Physician profile
Karim Mansour
NPI 1942238878
$1,933.30
in general payments reported to CMS, 2019-2025
25 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $120 · 2021: $285 · 2022: $456 · 2023: $442 · 2024: $163 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $323.35 | 2019-2025 | |
| Lilly USA, LLC | $296.49 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.85 | 2021-2023 | Tradjenta, Jardiance |
| Antares Pharma, INC. | $146.73 | 2021-2022 | |
| Novo Nordisk INC | $126.05 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $106.47 | 2021-2025 | |
| Amarin Pharma, INC. | $88.73 | 2020 | |
| Glaxosmithkline, LLC. | $84.16 | 2019-2023 | Bexsero |
| Boston Scientific Corporation | $56.31 | 2025 | Wavewriter Alpha Prime 16 |
| Seqirus USA INC | $47.79 | 2021-2025 | Fluad, Flucelvax |
| Janssen Pharmaceuticals, INC | $46.75 | 2019-2023 | Spravato |
| Teva Pharmaceuticals USA, INC. | $46.58 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $43.66 | 2021 | |
| Abiomed | $41.96 | 2025 | |
| Amgen INC. | $41.42 | 2022-2023 | Evenity, Prolia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $37.36 | 2019-2022 | |
| Medtronic, INC. | $33.87 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $33.38 | 2019-2021 | |
| Cranial Technologies, INC | $29.23 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.77 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.33 | 2024 | Trulance, Xifaxan |
| Abbott Laboratories | $23.11 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.39 | 2023 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $19.78 | 2024 | Rexulti |
| Nevro Corp. | $19.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karim Mansour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.